vs
Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
CITIUS ONCOLOGY, INC. is the larger business by last-quarter revenue ($3.9M vs $3.9M, roughly 1.0× Opus Genetics, Inc.).
Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
CTOR vs IRD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $3.9M |
| Net Profit | $-5.5M | — |
| Gross Margin | 80.0% | — |
| Operating Margin | -133.2% | — |
| Net Margin | -140.3% | — |
| Revenue YoY | — | -10.2% |
| Net Profit YoY | 16.9% | 53.0% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $3.9M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.4M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-5.5M | — | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-8.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-7.5M | ||
| Q2 24 | — | $-7.8M | ||
| Q1 24 | — | $-7.1M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -133.2% | — | ||
| Q3 25 | — | -269.9% | ||
| Q2 25 | — | -309.0% | ||
| Q1 25 | — | -227.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -207.1% | ||
| Q2 24 | — | -748.9% | ||
| Q1 24 | — | -450.5% |
| Q4 25 | -140.3% | — | ||
| Q3 25 | — | -566.9% | ||
| Q2 25 | — | -257.5% | ||
| Q1 25 | — | -187.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -194.6% | ||
| Q2 24 | — | -698.3% | ||
| Q1 24 | — | -415.3% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.24 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.29 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $45.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.4M | $15.3M |
| Total Assets | $110.0M | $50.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | $45.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | — | $32.4M | ||
| Q1 25 | — | $41.8M | ||
| Q4 24 | — | $30.3M | ||
| Q3 24 | — | $36.6M | ||
| Q2 24 | — | $41.4M | ||
| Q1 24 | — | $47.2M |
| Q4 25 | $58.4M | $15.3M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | — | $34.3M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | $110.0M | $50.2M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $48.2M | ||
| Q4 24 | — | $36.9M | ||
| Q3 24 | — | $40.4M | ||
| Q2 24 | — | $44.8M | ||
| Q1 24 | — | $51.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | $-35.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.4M | $-35.3M | ||
| Q3 25 | — | $-6.2M | ||
| Q2 25 | — | $-10.3M | ||
| Q1 25 | — | $-9.0M | ||
| Q4 24 | — | $-25.6M | ||
| Q3 24 | — | $-5.1M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-5.7M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
